Cargando…

PSMA-Expression Is Highly Associated with Histological Subtypes of Renal Cell Carcinoma: Potential Implications for Theranostic Approaches

In renal cell carcinoma (RCC), accurate imaging methods are required for treatment planning and response assessment to therapy. In addition, there is an urgent need for new therapeutic options, especially in metastatic RCC. One way to combine diagnostics and therapy in a so-called theranostic approa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bui, Vinh Ngoc, Unterrainer, Lena M., Brendel, Matthias, Kunte, Sophie C., Holzgreve, Adrien, Allmendinger, Fabian, Bartenstein, Peter, Klauschen, Frederick, Unterrainer, Marcus, Staehler, Michael, Ledderose, Stephan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668989/ https://www.ncbi.nlm.nih.gov/pubmed/38002095 http://dx.doi.org/10.3390/biomedicines11113095

Ejemplares similares

Immature Plasma Cell Myeloma Mimics Metastatic Renal Cell Carcinoma on (18)F-PSMA-1007 PET/CT Due to Endothelial PSMA-Expression
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook
por: Kirchner, Maximilian A., et al.
Publicado: (2021)

Total Tumor Volume on (18)F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with (225)Ac-PSMA-I&T
por: Unterrainer, Lena M., et al.
Publicado: (2022)

(68)Ga-EMP-100 PET/CT—a novel method for non-invasive assessment of c-MET expression in non-small cell lung cancer
por: Unterrainer, Lena M., et al.
Publicado: (2022)

In response to: PSMA PET/CT cost-effectiveness analysis in the USA: a response to a published commentary
por: Holzgreve, Adrien, et al.
Publicado: (2023)

PSMA Expression in Glioblastoma as a Basis for Theranostic Approaches: A Retrospective, Correlational Panel Study Including Immunohistochemistry, Clinical Parameters and PET Imaging
por: Holzgreve, Adrien, et al.
Publicado: (2021)

Feasibility of [(68)Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma
por: Unterrainer, Lena M., et al.
Publicado: (2022)

Detection of Splenic Tissue Using (99m)Tc-Labelled Denatured Red Blood Cells Scintigraphy—A Quantitative Single Center Analysis
por: Holzgreve, Adrien, et al.
Publicado: (2022)

Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial
por: Holzgreve, Adrien, et al.
Publicado: (2023)

Can Radiomics Provide Additional Information in [(18)F]FET-Negative Gliomas?
por: von Rohr, Katharina, et al.
Publicado: (2022)

(18)F-FET PET Uptake Characteristics of Long-Term IDH-Wildtype Diffuse Glioma Survivors
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

Feasibility of Different Tumor Delineation Approaches for (18)F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

Response to (225)Ac-PSMA-I&T after failure of long-term (177)Lu-PSMA RLT in mCRPC
por: Ilhan, Harun, et al.
Publicado: (2020)

In response to: Anatomy of (18)F-GE180, a failed radioligand for the TSPO protein
por: Albert, Nathalie L., et al.
Publicado: (2020)

Towards standardization of (18)F-FET PET imaging: do we need a consistent method of background activity assessment?
por: Unterrainer, Marcus, et al.
Publicado: (2017)

Correction to: Next‑generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR‑targeting peptide [(18)F]SiTATE
por: Unterrainer, Marcus, et al.
Publicado: (2023)

Next-generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR-targeting peptide [(18)F]SiTATE
por: Unterrainer, Marcus, et al.
Publicado: (2023)

Molecular Imaging with (18)F-FDG PET/CT and (99m)Tc-MIBI SPECT/CT in Osteitis Fibrosa Cystica Generalisata
por: Holzgreve, Adrien, et al.
Publicado: (2021)

Finger Pain as an Uncommon Primary Manifestation of Lung Carcinoma
por: Holzgreve, Adrien, et al.
Publicado: (2023)

Biodistribution and dosimetry for combined [(177)Lu]Lu-PSMA-I&T/[(225)Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging
por: Delker, Astrid, et al.
Publicado: (2023)

Toward Single-Time-Point Image-Based Dosimetry of (177)Lu-PSMA-617 Therapy
por: Brosch-Lenz, Julia, et al.
Publicado: (2023)

Combination of pre-treatment dynamic [(18)F]FET PET radiomics and conventional clinical parameters for the survival stratification in patients with IDH-wildtype glioblastoma
por: Li, Zhicong, et al.
Publicado: (2022)

Longitudinal [(18)F]GE-180 PET Imaging Facilitates In Vivo Monitoring of TSPO Expression in the GL261 Glioblastoma Mouse Model
por: Holzgreve, Adrien, et al.
Publicado: (2022)

(68)Ga-EMP-100 PET/CT—a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma—first in-human biodistribution and imaging results
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

(18)F-FDG PET/CT for Response Assessment in Pediatric Sebaceous Carcinoma of the Parotid Gland
por: Holzgreve, Adrien, et al.
Publicado: (2020)

Advances in PSMA theranostics
por: Jeitner, Thomas M., et al.
Publicado: (2022)

(18)F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results
por: Mittlmeier, L. M., et al.
Publicado: (2020)

Monitoring of Tumor Growth with [(18)F]-FET PET in a Mouse Model of Glioblastoma: SUV Measurements and Volumetric Approaches
por: Holzgreve, Adrien, et al.
Publicado: (2016)

Metabolic patterns on [(18)F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment
por: Holzgreve, Adrien, et al.
Publicado: (2023)

Increased TSPO PET signal after radiochemotherapy in IDH-wildtype glioma—indicator for treatment-induced immune activation?
por: Quach, Stefanie, et al.
Publicado: (2022)

Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [(18)F]FET PET radiomics
por: Li, Zhicong, et al.
Publicado: (2021)

PSMA Theranostics: Science and Practice
por: Mokoala, Kgomotso, et al.
Publicado: (2021)

Voxel-wise analysis of dynamic (18)F-FET PET: a novel approach for non-invasive glioma characterisation
por: Vomacka, Lena, et al.
Publicado: (2018)

Prognostic Value of TSPO PET Before Radiotherapy in Newly Diagnosed IDH–Wild-Type Glioblastoma
por: Albert, Nathalie L., et al.
Publicado: (2023)

PSMA expression by microvasculature of thyroid tumors – Potential implications for PSMA theranostics
por: Bychkov, Andrey, et al.
Publicado: (2017)

Development of PSMA-PET-guided CT-based radiomic signature to predict biochemical recurrence after salvage radiotherapy
por: Spohn, Simon K. B., et al.
Publicado: (2023)

Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy
por: Rogowski, Paul, et al.
Publicado: (2021)

Investigation of image-based lesion and kidney dosimetry protocols for (177)Lu-PSMA-I&T therapy with and without a late SPECT/CT acquisition
por: Resch, Sandra, et al.
Publicado: (2023)

(18)F-FET PET radiomics-based survival prediction in glioblastoma patients receiving radio(chemo)therapy
por: Wiltgen, Tun, et al.
Publicado: (2022)

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy
por: Jones, Wallace, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hk5is9p03m1gm97i57c8e26nv1